CYTR On Other Exchanges
text size: T | T
Back to Snapshot
Company Description

Contact Info

11726 San Vicente Boulevard

Suite 650

Los Angeles, CA 90049

United States

Phone: 310-826-5648

Fax: 310-826-6139

CytRx Corporation operates as a biopharmaceutical research and development company that specializes in oncology. Clinical Development Programs Aldoxorubicin The company is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its modified version of the chemotherapeutic agent, doxorubicin. Aldoxorubicin combines the chemotherapeutic agent doxorubicin with a novel linker-molecule that binds specifically to albumin in the blood to allow for delivery of higher amounts of doxorubicin (3½ to 4 times) without the major dose-limiting toxicities seen with administration of doxorubicin alone. Aldoxorubicin is a conjugate of the chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and is believed to concentrate the drug at the site of tumors. In the first quarter of 2014, the company initiated under an special protocol assessment granted by the U.S. Food and Drug Administration a pivotal, global Phase 3 trial of aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed following treatment with chemotherapy. The company is evaluating aldoxorubicin in a global Phase 2b clinical trial in small cell lung cancer, a Phase 2 clinical trial in HIV-related Kaposi's sarcoma, a Phase 2 clinical trial in patients with late-stage glioblastoma (brain cancer), a Phase 1b trial in combination with ifosfamide in patients with soft tissue sarcoma, and a Phase 1b trial in combination with gemcitabine in subjects with metastatic solid tumors. It has completed a global Phase 2b clinical trial with aldoxorubicin as a first-line therapy for STS, a Phase 1b/2 clinical trial primarily in the same indication, a Phase 1b clinical trial of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors and a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors. In addition to aldoxorubicin, the company is completing pre-clinical development for DK049, a novel anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology. DK049 was created at its laboratory facility in Freiburg, Germany, and employs a proprietary linker that is both pH sensitive and requires a specific enzyme for the release of the cytotoxic payload. DK049 has demonstrated significant anti-tumor activity in multiple animal models implanted with human tumors, including non-small cell lung, ovarian and pancreatic cancers. The company anticipates filing an Investigational New Drug Application in the second half of 2016 prior to initiating a Phase 1 clinical trial. Research and Development Expenditures for research and development activities related to continuing operations were $43.4 million, for the year ended December 31, 2015. Intellectual Property As of December 31, 2015, the company held rights in 4 granted U.S. patents, 55 granted foreign patents, 3 pending U.S. applications, and 22 pending foreign patent applications covering aldoxorubicin and related technologies. The company’s intellectual property holdings relating to aldoxorubicin and related technologies include an exclusive license from KTB Tumorforschungs GmbH to U.S. and foreign patents and patent applications. Patents and applications that cover pharmaceutical compositions of aldoxorubicin, processes for their production, and their use in treatment methods, viral diseases, autoimmune diseases, and acute or chronic inflammatory diseases have unextended patent terms expiring between June 2020 and June 2034. Additionally, it has three pending U.S. provisional patent applications covering its LADR technology and DK049. License Agreements The company has an agreement with KTB for the license of patent rights held by KTB for the worldwide development and commercialization of aldoxorubicin. It also has a non-exclusive worldwide license to any additional technology that is claimed or disclosed in the licensed patents and patent applications for use in the field of oncology. History CytRx Corporation, a Delaware corporation, was founded in 1985. The company was incorporated in 1985.


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

CYTR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CYTR.
View Industry Companies

Industry Analysis


Industry Average

Valuation CYTR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 178.5x
Price/Book 1.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact CYTRX CORP, please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at